Developing a new class of drugs with the diversity and specificity of antibodies, coupled with the oral bioavailability of small molecules
- Year invested 2010
- Investment Stage Early
- Sectors
- Investment Status Historic
- Associated Team
- Website rapharma.com/
- Company Status IPO/Acquired (by UCB) (NASDAQ: RARX)